The Latest Breaking News on Pharma

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Persistent rate hikes by the Fed and rising odds of a recession have aggravated market turbulence and led investors to seek refuge in defensive sectors such as healthcare. Defensive stocks tend to perform well in declining markets due to the steady demand for their products. Hence, consistent dividend-yielding drug stocks…

U.S. health officials are warning doctors against overusing the lone drug available to treat monkeypox

Dublin-listed Open Orphan confirmed it is helping gardai in respect of the investigation

Leading pharmaceutical company Pfizer (PFE) did exceptionally well during the pandemic thanks to the high demand for its COVID-19 vaccine, and it still has enough growth prospects. The company’s focus on strengthening its pipeline via business acquisitions, product development, and approvals is expected to deliver impressive growth in the upcoming…

More than a year after the drug was supplied, payments to major pharma companies are stalled due to this violation.

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…

Biotech stock Ginkgo Bioworks (DNA) has fallen more than 60% year-to-date. The company has been making some acquisitions recently to aid its growth over the next few years. However, given its weak financials and unfavorable analyst estimates, it may not be wise to invest in this stock now. Continue reading….

While the country awaits federal approval of a new ALS drug, people in South Florida with the disease already are using it.

The omicron-specific booster vaccine hit the market — some wonder if it's worth getting

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz. Just days after the FDA’s move, the Centers for Disease Control and Prevention followed, recommending updated boosters for anyone age 12 and up who had received at least two doses of the original COVID-19…